Live Feeds
● TRACKER Updated 21d ago · 44 sources tracked

FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks

An advisory panel to the US Food and Drug Administration has endorsed Grail for its Galleri blood test, concluding that the benefits of the multi-cancer early detection screening outweigh its risks. This milestone endorsement moves the product closer to a landmark FDA approval. However, critics and medical experts warn that the screening test failed its own major trial and could increase false positives while wasting billions of dollars. The split effectiveness vote and concerns over insurance coverage leave key questions unresolved for investors and rivals waiting for the agency to finalize its clinical benefit determination.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (50)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ An advisory panel to the US Food and Drug Administration concluded that the benefits of Grail's Galleri blood test outweigh its risks.
  • ✓ The screening test moves closer to Food and Drug Administration approval.
🛡️ Source Corroboration: 44 independent reporting domains (90% confidence) ⏱ Read time: ~3 min

What changed

An FDA advisory council advanced Grail toward potential approval despite criticism over its trial data.

Live updates

  1. FDA Panel Backs Grail Cancer Test Despite Trial Questions

    An advisory panel to the US Food and Drug Administration has endorsed Grail for its Galleri blood test, concluding that the benefits of the multi-cancer early detection screening outweigh its risks. This milestone endorsement moves the product closer to a landmark FDA approval. However, critics and medical experts warn that the screening test failed its own major trial and could increase false positives while wasting billions of dollars. The split effectiveness vote and concerns over insurance coverage leave key questions unresolved for investors and rivals waiting for the agency to finalize its clinical benefit determination.

    Why it matters

    The regulatory review follows the Galleri trial, drawing intense scrutiny from cancer experts regarding the true promise and limitations of early multi-cancer screening. While the advisory recommendation marks a major commercial victory for Grail, broader financial and clinical viability depends heavily on future insurance policies and Medicare coverage decisions. Industry observers remain split on how the FDA will handle the specific claims allowed for the test after the divided committee vote.

    What is confirmed

    • An advisory panel to the US Food and Drug Administration concluded that the benefits of Grail's Galleri blood test outweigh its risks.
    • The screening test moves closer to Food and Drug Administration approval.

    Still unconfirmed

    • Grail's Galleri multicancer blood test flunked its own big trial, which could increase false positives and waste billions of dollars.
    • Insurance coverage and specific claims remain unconfirmed as rivals and investors wait for final agency action.

    What to watch next

    • Final decision by the US Food and Drug Administration on the Galleri blood test approval.
    • Subsequent decisions regarding Medicare and private insurance coverage for multi-cancer screening tests.
    • Clinical updates addressing the false positive rates and trial outcomes cited by critics.
    Sources used for this update (3)
    1. www.pharmawire.org — Grail's cancer blood test nears landmark FDA approval, but ...
    2. geneticliteracyproject.org — Viewpoint: RFK Jr.’s stacked FDA advisory council endorses ...
    3. www.medtechdive.com — 5 doctors weigh in on the promise, limitations of Grail’s ...
    confidence 90%

  2. FDA Panel Endorses Grail Galleri Test Despite Split Effectiveness Vote

    An FDA advisory panel voted that the benefits of Grail's Galleri blood test outweigh its risks, supporting its safety and effectiveness. While the endorsement moves the multi-cancer early detection test closer to approval, the effectiveness vote was split. This division, combined with panel advice against using early framing, leaves the test's specific claims, competitor strategies, and potential Medicare coverage unresolved. Investors and rivals remain uncertain about how the FDA will finalize the clinical benefit determination.

    Why it matters

    The Galleri test screens for over 50 types of cancer via a single blood draw. Commercial success depends on FDA approval and subsequent adoption by insurance providers and Medicare.

    What is confirmed

    • An FDA advisory panel voted in favor of Galleri regarding safety, effectiveness, and benefit-risk.
    • The panel advised against early framing for the test.

    Still unconfirmed

    • The split effectiveness vote may leave Medicare coverage and rival strategies unsettled.
    • NCI Director Anthony Letai has expressed views regarding multi-cancer detection tests and Galleri.

    What to watch next

    • The final FDA decision on commercial approval
    • Medicare coverage determinations for multi-cancer early detection tests
    Sources used for this update (8)
    1. github.com — nocache/README at master · Feh/nocache · GitHub
    2. classic.yarnpkg.com — nocache - Yarn
    3. developer.mozilla.org — Cache-Control header - HTTP | MDN - MDN Web Docs
    4. directory.fsf.org — Nocache - Free Software Directory
    5. www.tek-tips.com — What does NOCACHE do? - Tek-Tips
    6. github.com — GitHub - helmetjs/nocache: Middleware to disable client-side...
    7. cancerletter.com — As FDA sidesteps the question of Galleri’s clinical benefit ...
    8. insights.citeline.com — Galleri Panel Aftermath: What Investors And Rivals See Next ...
    confidence 90%

  3. Grail Galleri Test Nears FDA Approval Following Advisory Panel Win

    Grail moves closer to commercial market approval for its Galleri cancer blood test after receiving a positive endorsement from an FDA advisory panel. The test screens for over 50 types of cancer using a single blood draw, but financial hurdles remain on the horizon. Insurance companies are exercising caution regarding the long-term cost-benefit profile of multi-cancer early detection tests. Stock performance has responded positively, hitting a 12-month high following the panel decision, though future financial success relies heavily on insurer adoption rates and test pricing.

    Why it matters

    The recent panel endorsement represents a critical milestone for multi-cancer early detection technology. Securing formal agency approval is expected to assist commercialization efforts. However, broader financial viability depends on how much insurers are willing to pay for the screening.

    What is confirmed

    • Grail's Galleri test moves closer to market approval following a positive advisory panel endorsement.
    • Insurers remain cautious about the long-term cost-benefit profile of multi-cancer early detection.

    Still unconfirmed

    • Grail stock hit a 12-month high after its FDA panel win.

    What to watch next

    • A formal FDA decision on the Galleri test approval
    • Insurer adoption decisions and pricing agreements for the test
    Sources used for this update (3)
    1. lifescivoice.com — Grail's Cancer Blood Test Nears Landmark FDA Approval
    2. hgbr.org — Grail Faces Pricing Hurdles Following FDA Advisory Panel ...
    3. www.fool.com — Grail Stock Hit a 12-Month High After Its FDA Panel Win. But ...
    confidence 90%

  4. FDA advisory panel backs Grail's Galleri cancer blood test

    An FDA advisory panel voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks for adults age 50 or older. The test screens for over 50 types of cancer from a single blood draw. The panel was divided 6-4 on the test's effectiveness. The test now awaits a formal FDA decision.

    Why it matters

    The Galleri test's approval would provide a new screening option for cancer, which is one of the leading causes of death worldwide. If approved, the test could potentially detect cancers at an early stage, improving treatment outcomes. The test's developer, Grail, has been working on the Galleri test for several years.

    What is confirmed

    • The FDA advisory panel voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks for adults age 50 or older.
    • The Galleri test screens for over 50 types of cancer from a single blood draw.
    • The panel was divided 6-4 on the test's effectiveness.

    What to watch next

    • FDA's formal decision on the Galleri test
    • Potential insurance coverage for the test
    • Results from further trials or studies on the test's effectiveness
    Sources used for this update (4)
    1. www.nasmeddiagnostic.com — Multi-Cancer Blood Test Moves Closer to FDA Approval
    2. www.thedailyupside.com — Grail Jumps as Cancer Test Nears Market - The Daily Upside
    3. www.medicaldaily.com — Cancer Blood Test Galleri Nears FDA Decision as Screening ...
    4. www.clinicaltrialvanguard.com — FDA Advisory Panel Votes 7-2 to Support Galleri Multi-Cancer ...
    confidence 100%

  5. FDA advisory panel endorses Grail's cancer blood test

    An FDA advisory panel voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks for adults age 50 or older. The test screens for over 50 types of cancer. The panel was divided 6-4 on the test's effectiveness. The test now awaits a formal FDA decision.

    Why it matters

    The Galleri test detects cancer signals in apparently healthy people with a single blood draw. If approved, it could be the first widely available blood test for multiple types of cancer. Existing screening methods often focus on specific cancer types. The test's approval could change cancer screening practices.

    What is confirmed

    • The FDA advisory panel voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks.
    • The test screens for more than 50 types of cancer.
    • The panel was divided 6-4 on the test's effectiveness.
    • The test is designed to spot signs of various cancers in apparently healthy people with a single blood draw.

    What to watch next

    • FDA's formal decision on the Galleri test's approval
    • Potential insurance coverage for the test if approved
    • Further studies on the test's effectiveness and reliability
    Sources used for this update (3)
    1. www.dlnnews.com — FDA panel endorses first-of-a-kind cancer blood test from Grail
    2. finance.yahoo.com — Grail's cancer blood test nears landmark FDA approval, but ...
    3. www.cherokeephoenix.org — FDA panel endorses first-of-a-kind cancer blood test from ...
    confidence 100%

  6. FDA panel recommends approval of Grail Galleri cancer blood test

    An FDA advisory panel voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks for adults age 50 or older. The test screens for more than 50 types of cancer, including some without existing screening alternatives. While the panel recommended approval, members were divided 6-4 on the test's effectiveness, and some expressed doubt regarding its reliability. The test now awaits a formal decision from the FDA, which will determine if the screening can be widely adopted and covered by insurance providers.

    Why it matters

    Early detection allows tumors to be treated more effectively. This specific test is a multi-cancer early detection tool that uses a single blood draw to identify various malignancies. Formal FDA approval is required before Medicare or private insurers typically cover the cost for patients.

    What is confirmed

    • The FDA advisory panel voted 7-2, with one abstention, that the benefits of Galleri outweigh the potential risks for adults age 50 years or older.
    • The Galleri blood test is designed to detect more than 50 types of cancer.
    • Panel members were split 6-4 on the question of the test's effectiveness.
    • The FDA advisory panel recommended that the agency approve the test.

    Still unconfirmed

    • The recommendation for approval is expected to benefit Samsung Electronics and Samsung C&T.
    • The panel wants more data on whether the testing reduces mortality.

    What to watch next

    • The final FDA decision on formal approval for the Galleri test.
    • Determinations by Medicare and private insurers regarding coverage of the screening cost.
    Sources used for this update (25)
    1. medicalxpress.com — FDA panel narrowly backs multi-cancer blood test despite doubts it works
    2. www.thecardiologyadvisor.com — FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works
    3. www.fda.gov — U.S. Food and Drug Administration
    4. www.fda.gov — Drugs | FDA
    5. en.wikipedia.org — Food and Drug Administration - Wikipedia
    6. www.usa.gov — Food and Drug Administration (FDA) | USAGov
    7. www.fda.gov — What We Do | FDA
    8. www.statnews.com — FDA expert panel endorses Grail's Galleri multi-cancer blood test
    9. www.marketscreener.com — US FDA advisers endorse Grail cancer test's benefits in key vote
    10. www.healio.com — FDA panel supports multicancer early detection test
    11. www.nbcnews.com — Cancer blood test faces high-stakes FDA review
    12. www.yahoo.com — FDA panel endorses Grail Galleri multi-cancer blood test - Yahoo
    confidence 90%

  7. FDA Advisory Panel Endorses Grail Multi-Cancer Blood Test

    An FDA advisory panel voted that the benefits of Grail's multi-cancer early detection blood test outweigh its risks. The test screens for 50 different types of cancer. While the panel provides a positive recommendation, the test still requires formal FDA approval before it can be widely adopted. This approval is the primary factor determining if Medicare and other private health insurers will cover the cost of the screening for patients.

    Why it matters

    Early detection of cancer typically improves survival rates but often requires invasive procedures. A single blood test for 50 cancers would simplify screening. The PATHFINDER 2 study evaluated the performance and safety of this specific detection method.

    What is confirmed

    • An FDA advisory panel endorsed the Grail blood test for cancer.
    • The panel stated that the benefits of the test outweigh the risks.
    • The blood test screens for 50 types of cancer.

    What to watch next

    • Official FDA approval decision
    • Medicare and insurance coverage determinations
    Sources used for this update (5)
    1. Nature — Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
    2. STAT — FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
    3. Reuters — US FDA advisers endorse Grail cancer test's benefits in key vote
    4. The Washington Post — One blood test could screen you for 50 cancers. Here’s why it’s controversial.
    5. MarketWatch — This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community